Uroprotective and Hepatoprotective Potential of Anagallis arvensis against the Experimental Animal Model

Table 5

Effect of A. arvensis on blood lipid profile.

Groups	Cholesterol (mg/dl)	TG (mg/dl)	HDL (mg/dl)	LDL (mg/dl)	VLDL (mg/dl)	Total lipids (mg/dl)
Control	86.00 ± 2.309	81.33 ± 0.88	25.66 ± 0.66	43.66 ± 1.20	19.00 ± 1.73	455.65 ± 5.60
Diseased control	110.00 ± 4.93	95.66 ± 1.45	18.66 ± 0.88	58.66 ± 4.09	26.33 ± 0.88	509.31 ± 2.40
Standard drug treated	82.66 ± 1.76	74.33 ± 2.18	24.66 ± 0.33	46.00 ± 1.00	15.66 ± 1.20	443.31 ± 5.04
MEOAA (250 mg/kg)	84.64 ± 0.33	75.66 ± 1.20	26.66 ± 1.20	37.33 ± 0.66	16.00 ± 0.57	440.29 ± 2.33
MEOAA (500 mg/kg)	77.33 ± 1.76	70.33 ± 0.33	28.00 ± 1.52	29.00 ± 0.57	14.00 ± 1.52	418.66 ± 3.93

Data have been presented as Mean ± SEM. Determination of the level of cholesterol, TG, HDL, LDL, VLDL, and total lipids for control, diseased control (paracetamol 250 mg/kg), standard drug (silymarin 50 mg/kg), and MEOAA (250 mg/kg and 500 mg/kg) treated groups of rats ( compared to the control group, compared to the diseased control group; n = 4) (MEOAA; methanol extract of Anagallis arvensis, TG; triglycerides, HDL; high density lipoproteins, LDL; low-density lipoproteins, VLDL; very low density lipoproteins).